1. Home
  2. FCAP vs RCEL Comparison

FCAP vs RCEL Comparison

Compare FCAP & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Capital Inc.

FCAP

First Capital Inc.

N/A

Current Price

$48.15

Market Cap

125.9M

Sector

Finance

ML Signal

N/A

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$3.50

Market Cap

114.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCAP
RCEL
Founded
1891
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
125.9M
114.3M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
FCAP
RCEL
Price
$48.15
$3.50
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$11.75
AVG Volume (30 Days)
4.0K
204.3K
Earning Date
01-23-2026
11-06-2025
Dividend Yield
2.44%
N/A
EPS Growth
25.19
N/A
EPS
4.41
N/A
Revenue
$47,323,000.00
$72,401,000.00
Revenue This Year
N/A
$13.12
Revenue Next Year
N/A
$27.56
P/E Ratio
$11.52
N/A
Revenue Growth
15.22
20.59
52 Week Low
$28.50
$3.35
52 Week High
$53.85
$14.16

Technical Indicators

Market Signals
Indicator
FCAP
RCEL
Relative Strength Index (RSI) 69.75 36.87
Support Level $47.48 $3.42
Resistance Level $50.95 $3.93
Average True Range (ATR) 0.99 0.21
MACD 0.37 0.00
Stochastic Oscillator 97.55 11.94

Price Performance

Historical Comparison
FCAP
RCEL

About FCAP First Capital Inc.

First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: